Stevenage Bioscience Catalyst launches accelerator program for biotech start-ups
The UK bioscience catalyst will invite selected start-ups to take part in the 18-week DATA program, which is offered at no cost, and runs from May.
Participants will have the opportunity to learn from experts, network, and build their expertise in structuring deals, accessing data, intellectual property and attracting funding.
At the end of the program, founders will be given the chance to pitch their idea in front of leading investors and pharmaceutical experts.
Dr Sally Ann Forsyth OBE, CEO at SBC, said, “At Stevenage Bioscience Catalyst, we are committed to enabling life science companies to connect, grow and succeed at every stage of their development. We are absolutely delighted to launch this program which will help start-ups build their expertise, supporting them to establish the funding and relationships they need to move to the next level. In addition, the start-up with the best pitch at the end of the program will be awarded £10,000 to continue their development.”
SBC launched its first DATA accelerator program last year, with 15 start-ups taking part. Participants included Glamourous AI, a company using artificial intelligence in drug discovery, which was acquired by X-Chem in October.
Stevenage Bioscience Catalyst was formed through a collaboration between the Department for Business, Energy and Industrial Strategy (BEIS), GlaxoSmithKline, Wellcome and Innovate UK.
The campus is home to major organisations including GSK, the Cell and Gene Therapy manufacturing centre, LifeArc and Cytiva alongside a growing cluster of start-ups. It is situated between London, Oxford and Cambridge.
More information about the accelerator can be found here.
